Nascimento, Renata Cristina Rezende Macedo doMueller, TanjaGodman, BrianStewart, Sean MacBrideHurding, SimonAcúrcio, Francisco de AssisGuerra Júnior, Augusto AfonsoTeodoro, Juliana AlvaresMorton, AlecBennie, MarionKurdi, Amanj Baker2021-12-072021-12-072020NASCIMENTO, R. C. R. M. do et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study. British Journal of Clinical Pharmacology, v. 86, p. 2349–2361, 2020. Disponível em: <https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14333>. Acesso em: 10 jun. 2021.1365-2125http://www.repositorio.ufop.br/jspui/handle/123456789/14111Aim: To assess associations between statin intensity and adherence, persistence and discontinuation of statin therapy in Scotland. Method: Retrospective cohort study, using linked electronic health records covering a period from January 2009 to December 2016. The study cohort included adult patients (≥18 years) newly initiating statins within Greater Glasgow and Clyde, Scot land. Study outcomes comprised adherence, discontinuation and persistence to treat ment, stratified by three exposure groups (high, moderate and low intensity). Discontinuation and persistence were calculated using the refill-gap and anniversary methods, respectively. Proportion of days covered (PDC) was used as a proxy for adherence. Kaplan-Meier survival curves and Cox proportional hazard models were used to evaluate discontinuation, and associations between adherence/persistence and statin intensity were assessed using logistic regression. Results: A total of 73 716 patients with a mean age of 61.4 ± 12.6 years were included; the majority (88.3%) received moderate intensity statins. Discontinuation rates differed between intensity levels, with high-intensity patients less likely to dis continue treatment compared to those on moderate intensity (prior cardiovascular disease [CVD]: HR 0.43 [95% CI 0.34-0.55]; no prior CVD: 0.80 [0.74-0.86]). Persis tence declined over time, and high-intensity patients had the highest persistence rates. Overall, 52.6% of patients were adherent to treatment (PDC ≥ 80%), but adher ence was considerably higher among high-intensity patients (63.7%). Conclusion: High-intensity statins were associated with better persistence and adherence to treatment, but overall long-term persistence and adherence remain a challenge, particularly among patients without prior CVD. This needs addressing.en-USabertoCardiovascular diseaseDrug utilisationArtigo publicado em periodicoThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. Fonte: o PDF do artigo.https://doi.org/10.1111/bcp.14333